Failed phase 2 lipolysis candidate with modest human signal and no clear research frontier
Look, the concept behind AOD-9604 is genuinely interesting: take the C-terminal region of hGH (residues 176-191), add a tyrosine at the N-terminus, and you theoretically get the lipolytic activity of growth hormone without the IGF-1-mediated growth effects, the diabetogenic risk, or the need to suppress endogenous GH secretion. That’s a clean hypothesis. The problem is that the clinical data didn’t back it up at the level you’d need.
The Metabolic Pharmaceuticals phase 2 work showed modest weight loss and fat mass reduction in obese subjects. “Modest” is doing a lot of heavy lifting in that sentence. The compound didn’t advance because regulators and the company agreed the efficacy signal wasn’t sufficient for a marketed obesity drug. That’s not a story of a mechanism being disproven. The lipolytic activity appears real. But it is a story of a mechanism that, when translated to humans at tolerable doses, produces underwhelming effect sizes.
That historical context matters a lot right now. The fat loss peptide landscape in 2025-2026 is absolutely dominated by the GLP-1 and dual/triple incretin story. Semaglutide delivers 10-15% body weight loss in clinical practice. Tirzepatide is hitting 20%+. Retatrutide is pushing even further. Against that backdrop, “modest fat mass reduction” from a subcutaneous peptide with a plasma half-life under an hour looks very hard to justify as a primary research target. You’re working in a therapeutically crowded space where the competition has completed phase 3 trials.
What we think still has value here is the probe angle. If your research question is specifically about the structure-activity relationships of hGH C-terminal fragments, the separation of the lipolytic versus somatotropic domains, or beta-3 adrenergic receptor involvement in hGH-driven lipolysis, AOD-9604 is a legitimate tool. Thats a narrow use case, but its a real one. The short half-life is honestly a research complication more than a feature; you’re dealing with rapid clearance that makes sustained exposure studies difficult unless you’re designing specific dosing regimens around it.
Nothing remarkable there. The compound doesnt have the replication problem of something like BPC-157: there are real human trials to point to, but those trials tell a story of limited clinical utility, not hidden potential. For a bench scientist trying to choose where to spend time in metabolic biology, AOD-9604 sits well below the frontier.